Table 1.

Study Details for Each Anticancer Drug

	Anticancer Drug Studied	Number of Studies Screened	Number of Arms Included	Number of Included Randomized Study Arms	Women, % (min-max)	Mean/Median Age, y (min-max)	Mean/Median Follow-Up, mo (min-max)	Total Number of AF Cases	Number of Patients Included
Alkylating agent	Dacarbazine	53	11	10	21.4-72.5	36-67	2-84	2	1,434
	Cisplatin	496	0	NA	NA	40-54	—	NA	NA
Androgen deprivation therapy	Abiraterone	55	14	6	0	63.1-75.1	3-60	30	2,290
Antimetabolites	Clofarabine	58	6	1	34.5-57.6	51-74.2	14-58	28	362
	Azacitidine	115	20	9	0-47.2	39.2-75.4	5-73	48	1,621
Anthracyclines	Daunorubicin	47	0	NA	NA	NA	2-84	NA	NA
	Idarubicin	29	0	NA	NA	NA	9-101	NA	NA
Kinase inhibitors	Ibrutinib	42	17	5	23.4-41.9	25-73.1	9-101	223	1,882
	Nilotinib	34	11	3	21.1-58.3	41.5-69.5	12-138	5	1,817
	Ponatinib	9	4	0	37.4-47.4	43-62	5-60	48	695
	Midostaurin	9	3	0	34.5-68.2	62-65	6-103	3	164
Immune checkpoint inhibitor	Ipilimumab	70	12	10	0-100	51.3-69.3	3-120	8	2,454
Immunomodulating agents	Aldesleukin	80	4	1	29.2-39.3	48.6-63.9	8-46	1	257
	Lenalidomide	229	31	6	0-76.8	36.2-77.8	2-94	34	2,718
	Pomalidomide	34	6	2	22.4-50.0	65-69	5-85	5	420
Monoclonal antibodies (anti-CD20)	Rituximab	489	18	7	28.6-67.7	38-71	6-92	4	2,609
	Obinutuzumab	30	2	1	38.8-47.7	59-59	10-27	NA	221
Proteasome inhibitor	Bortezomib	249	6	2	0-100	42-78	3-14	2	595
Taxane	Docetaxel	434	28	27	0-100	52-70.1	7-83	44	7,065
Total		2,562	193a	90	NA	NA	NA	485	26,604

A total of 193 study arms from 191 studies were included in the meta-analysis. All the values are mean or median (mean/median) and are expressed as min and max (min-max).

AF = atrial fibrillation; RCT = randomized controlled trial; NA = not applicable.

^a2 studies were eligible for 2 anticancer drugs.